Browse by Day

Friday, 13 December 2013

Friday | Saturday | top

08:00 - 10:00

Plenary Session 1: Novel Insights in the Biology of Allergic Responses in Immunotherapy
Great Lakes Grand Ballroom (Westin - Michigan Avenue)
 Chairpersons: Ruby Pawankar (Japan) Lanny J. Rosenwasser (US)
08:00 - 08:05
Welcoming Remarks
08:05 - 08:30
1-1: Personalized Medicine in Allergy and Asthma | Elliot Israel (United States)
08:30 - 08:55
1-2: Biologic Basis of the Allergic Response | Bruce S. Bochner (United States)
08:55 - 09:20
1-3: Overview of Allergen Immunotherapy and Tolerance | Cezmi Akdis (Switzerland)
09:20 - 09:45
1-4: New Treatments for Allergen Immunotherapy | Mübeccel Akdis (Switzerland)
09:45 - 10:00
Discussion

10:30 - 12:00

Biologics Track 1: Overview and Newer Uses of Anti-IgE
Great Lakes Grand Ballroom East (Westin - Michigan Avenue)
 Chairpersons: Claus Bachert (Belgium) , Nelson Rosario-Filho (Brazil)
10:30 - 10:35
Welcoming Remarks
10:35 - 10:55
1-5: The Role of IgE-Receptors in Airway Inflammation and Remodelling | Ruby Pawankar (Japan)
10:55 - 11:15
1-6: New Strategies with Anti-IgE in Allergic Diseases | Stephen T. Holgate (United Kingdom)
11:15 - 11:35
1-7: Oral Immunotherapy and Anti-IgE Antibody-Adjunctive Treatment for Food Allergy | Dale Umetsu (United States)
11:35 - 11:55
1-8: Anti-IgE in Chronic Urticaria | Sarbjit Saini (United States)
11:55 - 12:00
Discussion
Immunotherapy Track 1: Overview of Immunotherapy
Great Lakes Grand Ballroom West (Westin - Michigan Avenue)
 Chairpersons: Mario Sanchez Borges (Venezuela) , Suwat Benjaponpitak (Thailand)
10:30 - 10:35
Welcoming Remarks
10:35 - 10:55
1-9: Historical Perspective and Current Standards in Immunotherapy: Challenges and Unmet Needs | Richard F. Lockey (United States)
10:55 - 11:15
1-10: Subcutaneous Immunotherapy: Perspectives of Treatment Practices in the US and Europe | Oliver Pfaar (Germany)
11:15 - 11:35
1-11: Speaking the Same Language: Grading System for Subcutaneous Immunotherapy Systemic Reaction | Linda Cox (United States)
11:35 - 11:55
1-12: Management of Anaphylaxis during Immunotherapy | Phil Lieberman (United States)
11:55 - 12:00
Discussion

12:15 - 13:15

WAO Session WAO White Book Update and Allergen and Adherence Manifestos Launch
Great Lakes Grand Ballroom West (Westin - Michigan Avenue)
12:15 - 12:45
WAO White Book on Allergy Update | Ruby Pawankar (Japan)
12:45 - 12:53
Question and Answer
12:53 - 12:59
Manifesto on Adherence | G. Walter Canonica (Italy)
12:59 - 13:04
Question and Answer
13:04 - 13:10
Manifesto on Allergens | G. Walter Canonica (Italy)
13:10 - 13:15
Question and Answer

12:30 - 13:30

Poster Session 1
Michigan Ballroom (Westin - Michigan Avenue)
 Chairperson: Michael Foggs (US)
1000
1000: Efficacy and Safety of Specific Sublingual Immunotherapy with Carbamylated Allergoid Tablets of Ragweed Pollen: A Dose-Ranging Study | Enrico Compalati (Italy)
1001
1001: ALLERGENIUS®: an Expert System for the Interpretation of Allergen Microarrays | G. Walter Canonica (Italy)
1002
1002: Galectin-3 as Predictive Biomarker of Airways Remodeling Modulation in Omalizumab Treated Severe Asthma Patients | G. Walter Canonica (Italy)
1003
1003: Omalizumab is Effective in Allergic and Nonallergic Patients | Claus Bachert (Sweden)
1004
1004: The Effect of B7-H3 on CD4+ T Lymphocyte Activation in Vitro | Jun Sik Lee (South Korea)
1005
1005: Analysis of the mechanism of the allergen immunotherapy in Japanese cedar pollinosis | Takenori Haruna (Japan)
1006
1006: Baicalin From Scutellaria baicalensis Impairs Th1 Polarization Through Inhibition of Dendritic Cell Maturation | Jun Sik Lee (South Korea)
1007
1007: Universal Allergen Particle Generation for Inhaled Allergen Challenges in the Fraunhofer Environmental Challenge Chamber (ECC) | Jens M Hohlfeld (Germany)
1008
1008: Dialyzable Leukocyte Extracts as Adjuvant Treatment for Allergic Rhinitis | Toni Angela Homberg (Mexico)
1009
1009: AAAAI Survey on Allergen Immunotherapy (AIT) in Patients withSpecific Medical Conditions | Désirée Larenas-Linnemann (Mexico)
1010
1010: AAAAI Membership Experience with Venom Immunotherapy in Chronic Medical Conditions, Pregnancy and Young Children | Désirée Larenas-Linnemann (Mexico)
1011
1011: Potential Immunogenetic Associations Between Atopy and Metabolic Syndrome In Children | Laura Vidal (Mexico)
1012
1012: Safety and Efficacy Of Omalizumab In 10 Children With Asthma and Other Allergic Comorbidities | Ana Célia Costa (Portugal)
1013
1013: IL-4R Alpha Antibody Inhibits IgE Production and Airway Remodeling In Mouse Model Of House Dust Mite-Induced Eosinophilic Asthma | Ludmila Kelly (United States)
1014
1014: Omalizumab Efficiency In Patients With Allergic Rhinitis and Chronic Sinusitis | Lorena Rangel-Garza (Mexico)
1015
1015: : A Semi-rational Approach to Obtain a Thermostable Ionic Liquid Tolerant Bacterial Laccase Through Π- Type Interactions | Farideh Ghazi (Iran)
1016
1016: A Novel Peanut Allergoid Is Safe and Effective In a Murine Immunotherapy Model For Peanut Allergy | Hans Van Schijndel (Netherlands)
1017
1017: Preclinical and Clinical Findings: Role Of Periostin, IL-13, Lebrikzumab and Corticosteroid Resistance | Robert Townley (United States)
1018
1018: Evaluation Of CCR3 As a Basophil Activation Marker | Aaruni Khanolkar (United States)
1019
1019: Novel Allergy Vaccine Delivery System For Poison Ivy Urushiol (PI) and Peanut (PN) | Robert Coifman (United States)
1020
1020: Efficacy and Safety Of Sublingual Specific Immunotherapy With Pru p 3 In a Portuguese Population - Clinical and Immunological Evaluation During 12 Months | Ana Célia Costa (Portugal)
1021
1021: Use Of Paper Filter Discs For Measurement Of Local Biomarkers Of Nasal Mucosal Inflammation | Margot Berings (Belgium)
1022
1022: Angioedema and Angioedema Management From Asteria II: A Clinical Trial To Evaluate The Efficacy and Safety Of Omalizumab In Patients With Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU) Who Remain Symptomatic Despite H1 Antihistamine Treatment | James Zazzali (United States)
1023
1023: Dupilumab Suppresses Th2 Inflammation In Adult Asthma and Atopic Dermatitis | Brian Swanson (United States)
1024
1024: Accelerated Healing Of Full-Thickness Cutaneous Wound Using Purified Apitoxin From Asiatic Honey Bee (Apis cerana Fabricius) | Hua Chen (China)
1025
1025: Introduction To The Clinical Practice Of Molecular Allergology | Guy Tropper (Canada)
1026
1026: Randomized Clinical Trial to Evaluate Oral Dializable Leukocyte Extracts as Immunemodulator Treatment in Atopic Dermatitis | Jorge Galicia Carreón (Mexico)

13:30 - 15:00

Biologics Track 2: Novel Anti-Cytokines
Great Lakes Grand Ballroom East (Westin - Michigan Avenue)
 Chairpersons: Stephen T. Holgate (United Kingdom) , Francesca Levi-Schaffer (Israel)
13:30 - 13:35
Welcoming Remarks
13:35 - 13:55
1-13: IL-1 and IL-17 Cytokine Families: New Targets for Allergy Related Disorders | Lanny J. Rosenwasser (United States)
13:55 - 14:15
1-14: Anti-IL-5 in Asthma and Beyond | Parameswaran Nair (Canada)
14:15 - 14:35
1-15: Anti-IL-13 Prospects in Asthma | Sally Wenzel (United States)
14:35 - 15:00
Discussion
Immunotherapy Track 2: Sublingual Immunotherapy
Great Lakes Grand Ballroom West (Westin - Michigan Avenue)
 Chairpersons: Sandra Gonzalez-Diaz (Mexico) , Dana Wallace (US)
13:30 - 13:35
Welcoming Remarks
13:35 - 13:55
1-16: Recommendations for Appropriate Sublingual Immunotherapy Clinical Trials | Giovanni Passalacqua (Italy)
13:55 - 14:15
1-17: Current Status of Sublingual Immunotherapy in the United States | Michael Blaiss (United States)
14:15 - 14:35
1-18: WAO Position Paper Update on Sublingual Immunotherapy | G. Walter Canonica (Italy)
14:35 - 15:00
Discussion

15:30 - 17:00

Immunotherapy Track 3: Immunotherapy Targets for Food
Great Lakes Grand Ballroom West (Westin - Michigan Avenue)
 Chairpersons: Elham Hossny (Egypt) , Alessandro Fiocchi (Vatican City)
15:30 - 15:35
Welcoming Remarks
15:35 - 15:55
1-19: Use of Allergen Components: A New Era in Allergology | Motohiro Ebisawa (Japan)
15:55 - 16:15
1-20: Oral and Sublingual Immunotherapy for Food Allergy | Wesley Burks (United States)
16:15 - 16:35
1-21: Epicutaneous Immunotherapy for Food Allergy | Hugh Sampson (United States)
16:35 - 17:00
Discussion
Biologics Track 3: New Directions in Immunotherapy
Great Lakes Grand Ballroom East (Westin - Michigan Avenue)
 Chairpersons: Luis Caraballo (Colombia) , Zhang Luo (China)
15:30 - 15:35
Welcoming Remarks
15:35 - 15:55
1-22: Identification of Therapeutic Epitopes from Allergens | Alessandro Sette (United States)
15:55 - 16:15
1-23: Specific Immunoregulatory Epitopes in the Treatment of Allergic Disease | Mark Larché (Canada)
16:15 - 16:35
1-24: New Routes for Allergen Immunotherapy | Thomas Kündig (Switzerland)
16:35 - 17:00
Discussion

Saturday, 14 December 2013

Friday | Saturday | top

08:00 - 09:30

Biologics Track 4: Critical Novel Molecules for Allergic Diseases
Great Lakes Grand Ballroom East (Westin - Michigan Avenue)
 Chairpersons: Hirohisa Saito (Japan) , Tatiana Slavyanskaya (Russia)
08:00 - 08:05
Welcoming Remarks
08:05 - 08:25
2-1: Role of Thymic Stromal Lymphopoietin (TSLP) in Allergic Responses | Atsushi Kato (United States)
08:25 - 08:45
2-2: Role of Interleukin-33 in Innate-Type Immune Cells in Allergy | Susumu Nakae (Japan)
08:45 - 09:05
2-3: Advances in Synthetic Peptide Immuno-Regulatory Epitopes | Peter Creticos (United States)
09:05 - 09:30
Discussion
Immunotherapy Track 4: Other Novel Approaches to Immunotherapy
Great Lakes Grand Ballroom West (Westin - Michigan Avenue)
 Chairpersons: Richard F. Lockey (US) , Juan Carlos Ivancevich (Argentina)
08:00 - 08:05
Welcoming Remarks
08:05 - 08:25
2-4: Intralymphatic Immunotherapy | Gabriela Senti (Switzerland)
08:25 - 08:45
2-5: Recombinant Allergens: The Present and the Future | Rudolf Valenta (Austria)
08:45 - 09:05
2-6: Passive Immunization with Allergen-Specific IgG Antibodies for the Treatment and Prevention of Allergy | Rudolf Valenta (Austria)
09:05 - 09:30
Discussion

10:00 - 11:30

Biologics Track 5: Biomarkers, Biosimilars and Selection of Patients
Great Lakes Grand Ballroom East (Westin - Michigan Avenue)
 Chairpersons: Stanley Fineman (US) , Alessandro Fiocchi (Vatican City)
10:00 - 10:05
Welcoming Remarks
10:05 - 10:25
2-7: The Use of Biomarkers in Asthma Clinical Research Trials | Robert Lemanske (United States)
10:25 - 10:45
2-8: Inner City Asthma and Anti-IgE | William Busse (United States)
10:45 - 11:05
2-9: Biosimilars | Sergio Bonini (Italy)
11:05 - 11:30
Discussion
Immunotherapy Track 5: Social Consequences and Evidence Based Medicine and Immunotherapy
Great Lakes Grand Ballroom West (Westin - Michigan Avenue)
 Chairpersons: Linda Cox (US) , Giovanni Passalacqua (Italy)
10:00 - 10:05
Welcoming Remarks
10:05 - 10:25
2-10: The Consolidated Standards of Reporting Trials (CONSORT) Statement Applied to Allergen-Specific Immunotherapy with Inhalant Allergens | Jan Brozek (Canada)
10:25 - 10:45
2-11: Pharmacoeconomics of Immunotherapy | Cheryl Hankin (United States)
10:45 - 11:05
2-12: Selection of Patients for Sublingual versus Subcutaneous Immunotherapy | Désirée Larenas-Linnemann (Mexico)
11:05 - 11:30
Discussion

12:00 - 13:00

Poster Session 2
Michigan Ballroom (Westin - Michigan Avenue)
 Chairpersons: João Tebyrica (Brazil) , Ruchi Gupta (US)
2000
2000: A Case Study in Effective Innovative Strategic Multi-modal Recruitment Strategies in Difficult-to-Recruit Patient Populations: Study of Safety and Tolerability of Novel SLIT in an Adolescent Population | Anne Marie Salapatek (Canada)
2001
2001: Generation a hypoallergenic profilin from Amaranthus palmeri pollen | CESAR Manuel Landa (Mexico)
2002
2002: Transfer Factor May Provide Immunomodulation In Cutaneous Tuberculosis | Laura Vidal (Mexico)
2003
2003: Cat-PAD, The First In a New Class Of Synthetic Peptide Immuno-Regulatory Epitopes, Demonstrates a Favourable Safety and Tolerability Profile In Patients With Cat-Induced Rhinoconjunctivitis | Roderick Peter Hafner (United Kingdom)
2004
2004: Bio Immun(G)En Medicine Or How To Link Scientific Research and Daily Therapeutic Practice | Gilbert Glady (France)
2005
2005: Application Of a Standardized Titrated Nasal Provocation Test With HDM and Birch Pollen Extract In Multicentre Clinical Studies In Allergic Rhinitis | Diderik Boot (Netherlands)
2006
2006: Fel d 1 Derived Synthetic Peptide Immune-Regulatory Epitopes Improve Nasal Symptoms Of Cat Allergy 2 Years After Administration Of 4 Doses Over a 12 Week Period | Roderick Peter Hafner (United Kingdom)
2007
2007: Treatment With Fel d 1 Derived Synthetic Peptide Immune-Regulatory Epitopes Results In a Persistent Treatment Effect On Symptoms Of Cat Allergy 2 Years After Treatment With 4 Doses 4 Weeks Apart | Roderick Peter Hafner (United Kingdom)
2008
2008: Sublingual RUSH Immunotherapy | Ramandra Nath Mitra (India)
2009
2009: Clinical Substantiation Of Immunocorrective Therapy In Children With Atopic Dermatitis | Tatiana Slavyanskaya (Russia)
2010
2010: A Study Assessing The Safety and Efficacy Of Subcutaneous Immunotherapy With a Dust Mite Vaccine With The Adjuvant L-Tyrosine In a Highly Sensitized Population In a Latin-American City | Jorge F Maspero (Argentina)
2011
2011: A DNA Vaccine Immunotherapy For Japanese Red Cedar Allergy | Lawrence Weiner (United States)
2012
2012: House Dust Mite Sublingual Immunotherapy With Standardized Vaccines: Prescription and Adverse Events | Alexander Diaz Rodriguez (Cuba)
2013
2013: The Safety Of The United Allergy Services Immunotherapy Protocol | Frederick Schaffer (United States)
2014
2014: A Survey Of Respiratory Physicians' Opinion Of SIT In Asthma Treatment In Wuhan Of China | Rongfei Zhu (China)
2015
2015: Quality Of Life Improvement With Sublingual Immunotherapy: A Prospective Study Of Efficacy | Mary S. Morris (United States)
2016
2016: The Effect and Value Of Sublingual Immunotherapy: A Patient Survey | Mary S. Morris (United States)
2017
2017: Molecular Profiles Of IgE To Timothy Grass Allergens In Patients Screened For Grass Tablet Immunotherapy | Hendrik Nolte (United States)
2018
2018: Efficacy and Safety Of Grass Sublingual Immunotherapy Tablet (SLIT-T) Treatment In a Large Randomized Controlled Trial In North American Children and Adults | Hendrik Nolte (United States)
2019
2019: Grass Sublingual Immunotherapy Tablet (SLIT-T) Treatment Is Associated With Similar Efficacy and Safety In Children and Adults: Subgroup Analysis Of Data From a Large North American Trial | Hendrik Nolte (United States)
2020
2020: Effect Of Sublingual Immunotherapy Tablet (SLIT-T) Treatment On Daily Medication Score Using Alternative Scoring Methods Based On WAO Recommendations | Hendrik Nolte (United States)
2021
2021: The Incidence Of Adverse Reactions Induced By Subcutaneous Immunotherapy In An Allergy Center In Monterrey, México: A Retrospective Chart Review | Lorena Rangel (Mexico)
2022
2022: Sublingual Immunotherapy In The Treatment Of Allergic Rhinitis: Series Of Cases | Lorena Rangel-Garza (Mexico)

13:00 - 13:30

Special Lecture 1: Molecular Mechanisms and Treatment of Hereditary Angioedema (HAE)
Great Lakes Grand Ballroom (Westin - Michigan Avenue)
 Chairperson: Allen Kaplan (US)
13:00 - 13:05
Welcoming Remarks
13:05 - 13:25
2-13: Molecular Mechanisms and Treatment of Hereditary Angioedema (HAE) | Bruce Zuraw (United States)
13:25 - 13:30
Discussion

13:30 - 14:00

Keynote Lecture Personalized / Precision Medicine: Opportunities and Challenges
Great Lakes Grand Ballroom (Westin - Michigan Avenue)
 Chairperson: Carlos E. Baena-Cagnani (Argentina)
13:30 - 13:35
Welcoming Remarks
13:35 - 14:00
2-14: Speaker | Stephen J. Galli (United States)

14:00 - 14:45

WAO Presidential Session Advances in WAO: From Vision to Action
Great Lakes Grand Ballroom (Westin - Michigan Avenue)
 Chairperson: Paul A. Greenberger (US)
14:00 - 14:05
Welcoming Remarks
14:05 - 14:30
Advances in WAO: From Vision to Action | Ruby Pawankar (Japan)
14:30 - 14:45
WAO Awards Presentation

15:15 - 16:00

WAO Junior Member Session Practical Course on Immunotherapy
Great Lakes Grand Ballroom (Westin - Michigan Avenue)
 Chairpersons: Michael Blaiss (US) , Ignacio J. Ansotegui (Spain)
15:15 - 15:20
Welcoming Remarks
15:20 - 15:35
2-16: Current Status and Future Perspectives of Immunotherapy in Latin America and Cuba | Alexander Diaz Rodriguez (Cuba)
15:35 - 15:50
2-17: Use of New Technology to Improve Utilization and Adherence to Immunotherapy | Ves Dimov (United States)
15:50 - 16:00
Discussion

16:00 - 17:00

WAO & AAAAI Session Update on Urticaria Guidelines - This session is funded through an educational grant from Genentech
Great Lakes Grand Ballroom (Westin - Michigan Avenue)
 Chairpersons: Michael Blaiss (US) , Ignacio J. Ansotegui (Spain)
16:00 - 16:05
Welcoming Remarks
16:05 - 16:25
2-18: Overview of Acute and Chronic Urticaria | Bruce Zuraw (United States)
16:25 - 16:45
2-19: Chronic Urticaria: New Management Options | Paul A. Greenberger (United States)
16:45 - 17:00
Discussion